Miromatrix Medical Inc.’s stock MIRO, -2.80% jumped 230% in premarket trades on Monday after the company agreed to be acquired by United Therapeutics Corp.
for $3.25 per share in cash, or about $91 million. The deal also includes a milestone payment of $1.75 per share in cash upon the achievement of clinical development of Miromatrix’s development-stage, fully-implantable manufactured kidney product, Mirokidney by Dec. 31, 2025. The price of $3.25 a share amounts to a premium of approximately 170% to the 30-day volume-weighted average trading price of Miromatrix’s common stock as of Friday.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: